FOS and metabolic dysfunction-associated steatotic liver disease: Studies suggest that OGT plays an oncogenic role in non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC) through activating JNK/c-Jun/AP-1 cascade by increasing p-JNK, p-c-Jun protein expression and AP-1 activation.